Autres langues Neuronetics, Inc.

Actions

STIM

US64131A1051

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
3,49 ^USD	-0,85%		-8,16%	+20,34%

10/04	Neuronetics, Inc. annonce la publication de résultats cliniques significatifs dans Brain Stimulation : Recherche fondamentale, translationnelle et clinique en neuromodulation	CI
28/03	Neuronetics, Inc. annonce que John K. Bakewell, Joseph H. Capper et le Dr Wilfred E. Jaeger ne se présentent pas à la réélection du conseil d'administration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call	23/04
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital	10/04
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	10/04
Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	28/03
Neuronetics Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	28/03
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	27/03
NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression	26/03
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21	25/03
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise	25/03
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression	25/03
Neuronetics, Inc. Announces Clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy	25/03
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network	07/03
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network	07/03
Neuronetics, Inc. Announces 5-Year Exclusive Partnership with Transformations Care Network	07/03
Neuronetics : STIM Corporate Presentation March 2024	05/03
Neuronetics: Q4 Earnings Snapshot	05/03
Earnings Flash (STIM) NEURONETICS Reports Q4 Revenue $20.3M	05/03
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results	05/03
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Neuronetics, Inc.

Actions

STIM

US64131A1051

Autres langues

Filtres